Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Azurity Pharmaceuticals, Inc.
WARNING LETTER
•Azurity Pharmaceuticals, Inc.•March 2, 2023

Azurity Pharmaceuticals, Inc. – FDA Warning Letter, Mar 2, 2023

Record Details

The FDA inspected Azurity Pharmaceuticals, Inc. (FEI 3003395329) at 841 Woburn Street, Wilmington, MA, from February 2, 2023, to March 2, 2023. The inspection and subsequent website review revealed violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The firm manufactures unapproved new drug products, including FIRST® Lansoprazole, FIRST® Pantoprazole, FIRST® Metronidazole, and FIRST® Mouthwash BLM, which are prohibited from interstate commerce under sections 301(d) and 505(a) of the FD&C Act because they lack FDA-approved applications.

Additionally, significant Current Good Manufacturing Practice (CGMP) violations were identified, rendering the drug products adulterated under section 501(a)(2)(B) of the FD&C Act. Violations include: 1. Failure to thoroughly investigate unexplained discrepancies or failures of batches or components to meet specifications (21 CFR 211.192). The firm's investigations into unexplained discrepancies were inadequate, failing to identify root causes or implement effective CAPAs. 2. Failure to establish and follow an adequate written testing program for stability characteristics and to use results to determine storage conditions and expiration dates (21 CFR 211.166(a)). The firm

Company
Azurity Pharmaceuticals, Inc.
Inspection date
March 2, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Jill P. Furman (Director)
View Company Profile

ID · 8bbd1871-bfb2-4652-9195-d7b242d82ad8

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(d)21.U.S.C. 355(a)21 CFR 21021 CFR 21121 U.S.C. 321(g)(1)21 U.S.C. 321(p)(1)21 CFR 211.19221 CFR 211.166(a)21 U.S.C. 356c(a)

Full citation text and observation details available on the Dashboard.

Other documents for Azurity Pharmaceuticals, Inc.
  • EIR - 2022-02-24February 24, 2022
  • EIR - 2019-07-26July 26, 2019
  • CRL
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Azurity Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.